4-[[2,3-difluoro-4-(trifluoromethyl)phenyl]sulfonylmethyl]-N-(thiadiazol-5-yl)piperidine-1-carboxamide
C16H15F5N4O3S2 — CID 122484410
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[[2,3-difluoro-4-(trifluoromethyl)phenyl]sulfonylmethyl]-N-(thiadiazol-5-yl)piperidine-1-carboxamide
4-[[2,3-difluoro-4-(trifluoromethyl)phenyl]sulfonylmethyl]-N-(thiadiazol-5-yl)piperidine-1-carboxamide (PubChem CID 122484410) has the molecular formula C16H15F5N4O3S2 and a molecular weight of 470.45 g/mol. Its IUPAC name is 4-[[2,3-difluoro-4-(trifluoromethyl)phenyl]sulfonylmethyl]-N-(thiadiazol-5-yl)piperidine-1-carboxamide.
Molecular Properties
| Compound Name | 4-[[2,3-difluoro-4-(trifluoromethyl)phenyl]sulfonylmethyl]-N-(thiadiazol-5-yl)piperidine-1-carboxamide |
|---|---|
| PubChem CID | 122484410 |
| Molecular Formula | C16H15F5N4O3S2 |
| Molecular Weight | 470.45 g/mol |
| Exact Mass | 470.05 |
| IUPAC Name | 4-[[2,3-difluoro-4-(trifluoromethyl)phenyl]sulfonylmethyl]-N-(thiadiazol-5-yl)piperidine-1-carboxamide |
| SMILES | O=C(Nc1cnns1)N1CCC(CS(=O)(=O)c2ccc(C(F)(F)F)c(F)c2F)CC1 |
| InChI | InChI=1S/C16H15F5N4O3S2/c17-13-10(16(19,20)21)1-2-11(14(13)18)30(27,28)8-9-3-5-25(6-4-9)15(26)23-12-7-22-24-29-12/h1-2,7,9H,3-6,8H2,(H,23,26) |
| InChIKey | GNUKTMWOTKOJAM-UHFFFAOYSA-N |
| XLogP | 3.55 |
| TPSA | 92.26 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 470.45 |
| LogP ≤ 5 | 3.55 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122484410 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.